ASCO Conference Coverage
Filter News By:
Featured News
View all
More News
(Fred Hutch News Service) June 11, 2018 - The ASCO endorsement, published today in the Journal of Clinical Oncology, came from an expert panel that reviewed a set of clinical practice guidelines for integrative therapies put out by the...
(NCI/Cancer Currents Blog) June 5, 2018 - People diagnosed with hairy cell leukemia (HCL), an uncommon form of leukemia, may soon have an effective new treatment option, according to findings from an international phase 3 clinical trial.
(PharmaTimes [UK]) June 5, 2018 - AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival in prostate cancer patients taking a combination of Lynparza and abiraterone.
(Xconomy National) June 5, 2018 - At ASCO, there were two major themes: the feverish and flawed race to develop cancer immunotherapy combinations, and the progress of “tissue agnostic” cancer drugs, the advanced guard of precision...
(NPR/Shots blog) June 5, 2018 - Are some people getting too much treatment for their cancers? The answer, from the American Society of Clinical Oncology meeting in Chicago, is an emphatic yes.
(AstraZeneca) June 4, 2018 - AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today presented data, which showed clinical improvement in median radiologic progression-free survival (rPFS) with LYNPARZA® (olaparib) in combination...
(Pfizer) June 4, 2018 - Pfizer Inc. today announced overall survival (OS) data from the ARCHER 1050 trial evaluating dacomitinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)...
(The Telegraph [UK]) June 4, 2018 - One of AstraZeneca’s most important new drugs could help men with advanced prostate cancer, bringing the pharmaceutical company a step closer to its long-term goal of generating $45bn (£33.6bn) of...
(BioPharma Dive) June 5, 2018 - Data unveiled Monday from a Phase 3 study found patients with high levels of a biomarker appeared to derive greater benefit from Bristol-Myers Squibb's Opdivo, particularly when paired with the pharma's...
(TESARO) June 4, 2018 - TOPACIO data for ZEJULA® (niraparib) in combination with an anti-PD-1 mAb highlight promising activity in platinum-resistant/refractory ovarian cancer and triple-negative breast cancer beyond patients with BRCA...
Expert Videos

OBR Tweets

Aug 04
William McGivney, PhD: It is interesting to see "record profits" for managed care companies in the face of the Covi… https://t.co/rT8cnBEEZu

Jul 27
Dean Gesme, MD: Trump gave just Congress and manufacturers 30 days to develop and pass a Part B Medicare drug acqui… https://t.co/pK6VjPFbo0

Jul 24
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ZcPRjbtKvL

Jul 24
OBR spoke at length with ASCO's president, Dr. Howard "Skip" Burris, about the pros and cons of #ASCO20's virtual f… https://t.co/9Bq8oJfj5c

Jul 23
A lack of interoperability in the nation's healthcare system has detracted from patient care, leading to poor healt… https://t.co/t6o30WgMjU

Jul 20
William McGivney, PhD: It is with fondness and a smile that I read the story about the distress thermometer now bei… https://t.co/oWDatBpFnu

Jul 15
H. Jack West, MD: Unclear to me why this doesn't raise alarm bells as a conflict of interest. Why is an institution… https://t.co/7pAHP6YnWx

Jul 09
H. Jack West, MD: The benefit of low dose chest CT screening for lung cancer remains somewhat controversial, but th… https://t.co/8wOgsSCY7q

Jul 08
Howard S. Hochster, MD: While a "complete response" is great for our patients, the Complete Response Letter was les… https://t.co/yQGkfvpMCF

Jul 02
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ve0XD0cWDY